• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Privia Health Announces Appointment of Lance V. Berberian to its Board of Directors

    7/8/25 9:00:00 AM ET
    $LH
    $PRVA
    Medical Specialities
    Health Care
    Medical/Nursing Services
    Health Care
    Get the next $LH alert in real time by email

    ARLINGTON, Va., July 08, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced the appointment of Lance V. Berberian to its Board of Directors, effective July 15, 2025. He has also been named a member of the Audit Committee of the Board. Following the appointment of Mr. Berberian, the Board will comprise 10 directors.

    "We are excited to welcome Lance to our Board of Directors," said David King, Chairman of the Board, Privia Health Group, Inc. "Lance brings extensive technology strategy and digital transformation experience to the Board, including IT governance, infrastructure management and cybersecurity. We believe his expertise will be invaluable to Privia Health as we continue to grow our business and build scaled provider networks across the U.S."

    Mr. Berberian is a technology strategist with over 30 years of experience specializing in digital transformation and corporate governance. From 2014 to October 2024, he served as EVP and Chief Information and Technology Officer at Labcorp Holdings Inc. (NYSE:LH), overseeing a team of 5,000 people focused on IT strategy, cybersecurity, AI, product development, and data management. Prior to Labcorp, Mr. Berberian held CIO roles at IDEXX Laboratories, Kellstrom Aerospace, Interim HealthCare and Quest Diagnostics.

    Mr. Berberian currently serves on the Elon University Board of Trustees and previously chaired the NC State Computer Science Strategic Advisory Board. He holds a bachelor's degree in business administration and information technology from Thomas Edison State College.

    About Privia Health

    Privia Health™ is one of the largest physician enablement companies in the United States with a presence in 15 states and the District of Columbia. Privia builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. Privia collaborates with medical groups, health plans and health systems to optimize 1,200+ physician practices, improve the patient experience for 5.2+ million patients, and reward 4,800+ physicians and advanced practitioners for delivering high-value care.

    Privia's mission is to transform healthcare delivery to achieve better outcomes, lower costs, and improve the health of communities and the well-being of providers. For more information, visit priviahealth.com and connect with us on LinkedIn.

    Safe Harbor Statement

    This release may contain forward-looking statements within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in filings with the Securities and Exchange Commission ("SEC"), including those under "Risk Factors" therein. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Forward-looking statements speak only as of the date made. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

    Contact:

    Robert Borchert

    SVP, Investor & Corporate Communications

    [email protected]         

    817.783.4841



    Primary Logo

    Get the next $LH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LH
    $PRVA

    CompanyDatePrice TargetRatingAnalyst
    Labcorp Holdings Inc.
    $LH
    7/10/2025$260.00Buy → Hold
    HSBC Securities
    Labcorp Holdings Inc.
    $LH
    4/2/2025$276.00Buy
    Redburn Atlantic
    Labcorp Holdings Inc.
    $LH
    3/4/2025$250.00 → $300.00Neutral → Buy
    Citigroup
    Privia Health Group Inc.
    $PRVA
    1/10/2025$25.00Buy
    Needham
    Labcorp Holdings Inc.
    $LH
    1/7/2025$260.00 → $265.00In-line → Outperform
    Evercore ISI
    Privia Health Group Inc.
    $PRVA
    12/16/2024Outperform
    Macquarie
    Labcorp Holdings Inc.
    $LH
    12/10/2024$265.00 → $275.00Buy
    Jefferies
    Labcorp Holdings Inc.
    $LH
    10/30/2024Hold → Buy
    HSBC Securities
    More analyst ratings

    $LH
    $PRVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Legal Officer Van Der Vaart Sandra D exercised 3,903 shares at a strike of $131.43 and sold $1,059,371 worth of shares (3,903 units at $271.42) (SEC Form 4)

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    8/15/25 10:55:59 AM ET
    $LH
    Medical Specialities
    Health Care

    President & CEO Schechter Adam H sold $1,505,440 worth of shares (5,643 units at $266.78), decreasing direct ownership by 6% to 93,319 units (SEC Form 4)

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    8/13/25 12:29:58 PM ET
    $LH
    Medical Specialities
    Health Care

    Director Gilliland Dwight Gary sold $529,900 worth of shares (2,000 units at $264.95), decreasing direct ownership by 23% to 6,656 units (SEC Form 4)

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    8/1/25 8:44:32 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    $PRVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease

    Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today the availability of the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first blood-based in-vitro diagnostic (IVD) test cleared by the U.S. Food and Drug Administration (FDA) to aid in the diagnosis of Alzheimer's disease through early detection of the amyloid plaques associated with the disease in appropriate patients. Developed by Fujirebio Diagnostics, Inc., the test is now available nationwide through Labcorp.

    8/18/25 7:00:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Privia Health Reports Second Quarter 2025 Financial Results

    Very Strong First Half Performance Across All Key Operating and Financial MetricsImplemented Providers +13.8% and Practice Collections +18.5% compared to 2Q'24Guidance Raised to Above High End of Range for Practice Collections, GAAP Revenue, Platform Contribution and Adjusted EBITDA c ARLINGTON, Va., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) today announced financial results for the second quarter ended June 30, 2025. Second Quarter Performance   For the Three Months Ended June 30,  ($ in millions, except per share amounts)  2025  2024 Change (%)       Total revenue $521.2 $422.3 23.4%Gross profit $112.8 $98.3 14.8%Operating income $3.3 $5.1 (34.6)%Ne

    8/7/25 6:00:00 AM ET
    $PRVA
    Medical/Nursing Services
    Health Care

    Labcorp Introduces Test Finder, a First-of-Its-Kind Generative AI Tool to Simplify Lab Test Search

    Test Finder interprets provider questions in context to deliver curated, clinically relevant results, going beyond traditional search Developed in collaboration with Amazon Web Services, Test Finder is now available on Labcorp.com BURLINGTON, N.C., July 30, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Test Finder, a first-of-its-kind generative AI tool developed with Amazon Web Services (AWS). Designed to simplify lab test selection, Test Finder enables healthcare providers to ask questions or describe conditions in plain language and receive curated test recommendations—enhancing the user experienc

    7/30/25 7:12:00 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    $PRVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Labcorp Holdings Inc. downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded Labcorp Holdings Inc. from Buy to Hold and set a new price target of $260.00

    7/10/25 9:03:30 AM ET
    $LH
    Medical Specialities
    Health Care

    Redburn Atlantic initiated coverage on Labcorp Holdings Inc. with a new price target

    Redburn Atlantic initiated coverage of Labcorp Holdings Inc. with a rating of Buy and set a new price target of $276.00

    4/2/25 8:50:29 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Holdings Inc. upgraded by Citigroup with a new price target

    Citigroup upgraded Labcorp Holdings Inc. from Neutral to Buy and set a new price target of $300.00 from $250.00 previously

    3/4/25 7:36:42 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    $PRVA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $LH
    $PRVA
    SEC Filings

    View All

    Director Boehler Adam bought $6,006 worth of shares (364 units at $16.50) (SEC Form 4)

    4 - Privia Health Group, Inc. (0001759655) (Issuer)

    6/13/24 4:05:22 PM ET
    $PRVA
    Medical/Nursing Services
    Health Care

    Boehler Adam bought $87,549 worth of shares (5,306 units at $16.50) (SEC Form 4)

    4 - Privia Health Group, Inc. (0001759655) (Issuer)

    5/31/24 4:13:08 PM ET
    $PRVA
    Medical/Nursing Services
    Health Care

    Boehler Adam bought $70,577 worth of shares (4,280 units at $16.49) (SEC Form 4)

    4 - Privia Health Group, Inc. (0001759655) (Issuer)

    5/29/24 4:08:14 PM ET
    $PRVA
    Medical/Nursing Services
    Health Care

    SEC Form 144 filed by Labcorp Holdings Inc.

    144 - LABCORP HOLDINGS INC. (0000920148) (Subject)

    8/11/25 9:50:12 AM ET
    $LH
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Privia Health Group Inc.

    10-Q - Privia Health Group, Inc. (0001759655) (Filer)

    8/7/25 9:02:02 AM ET
    $PRVA
    Medical/Nursing Services
    Health Care

    Privia Health Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Privia Health Group, Inc. (0001759655) (Filer)

    8/7/25 6:10:47 AM ET
    $PRVA
    Medical/Nursing Services
    Health Care

    $LH
    $PRVA
    Financials

    Live finance-specific insights

    View All

    Privia Health Reports Second Quarter 2025 Financial Results

    Very Strong First Half Performance Across All Key Operating and Financial MetricsImplemented Providers +13.8% and Practice Collections +18.5% compared to 2Q'24Guidance Raised to Above High End of Range for Practice Collections, GAAP Revenue, Platform Contribution and Adjusted EBITDA c ARLINGTON, Va., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) today announced financial results for the second quarter ended June 30, 2025. Second Quarter Performance   For the Three Months Ended June 30,  ($ in millions, except per share amounts)  2025  2024 Change (%)       Total revenue $521.2 $422.3 23.4%Gross profit $112.8 $98.3 14.8%Operating income $3.3 $5.1 (34.6)%Ne

    8/7/25 6:00:00 AM ET
    $PRVA
    Medical/Nursing Services
    Health Care

    Labcorp Announces 2025 Second Quarter Results

    Raises Full-Year Guidance Financial results from Operations for second quarter 2025 versus second quarter 2024:Revenue: $3.53 billion versus $3.22 billionDiluted EPS: $2.84 versus $2.43Adjusted EPS: $4.35 versus $3.94Raised Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance:Revenue guidance narrowed to 7.5% to 8.6%; midpoint raised by 70 basis pointsAdjusted EPS range narrowed to $16.05 to $16.50; midpoint raised by $0.23Free Cash Flow range of $1.13 billion to $1.28 billion; midpoint raised by $25 millionBroadened our partnerships with hospitals, health systems and regional/local labs and enhanced access to comprehensive testing and laboratory servicesIntroduced several new tests

    7/24/25 6:50:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Privia Health to Report Second Quarter 2025 Results on Thursday, August 7

    ARLINGTON, Va., July 10, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) today announced that it expects to release financial results for its second-quarter and six-month periods ended June 30, 2025 before market open on Thursday, August 7, 2025. The press release is expected to be publicly disseminated by 7:00 am ET and will also be available on the Company's Investor Relations website at ir.priviahealth.com. Privia Health management will host a conference call beginning at 8:00 am ET on the same day, Thursday, August 7, to discuss the results and management's outlook for future financial and operational performance. You can visit ir.priviahealth.com/news-and-events/eve

    7/10/25 9:00:00 AM ET
    $PRVA
    Medical/Nursing Services
    Health Care

    $LH
    $PRVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Privia Health Group Inc.

    SC 13G/A - Privia Health Group, Inc. (0001759655) (Subject)

    11/14/24 5:20:21 PM ET
    $PRVA
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Privia Health Group Inc.

    SC 13G/A - Privia Health Group, Inc. (0001759655) (Subject)

    11/12/24 10:34:17 AM ET
    $PRVA
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Privia Health Group Inc.

    SC 13G/A - Privia Health Group, Inc. (0001759655) (Subject)

    7/10/24 1:14:41 PM ET
    $PRVA
    Medical/Nursing Services
    Health Care

    $LH
    $PRVA
    Leadership Updates

    Live Leadership Updates

    View All

    Privia Health Announces Appointment of Lance V. Berberian to its Board of Directors

    ARLINGTON, Va., July 08, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced the appointment of Lance V. Berberian to its Board of Directors, effective July 15, 2025. He has also been named a member of the Audit Committee of the Board. Following the appointment of Mr. Berberian, the Board will comprise 10 directors. "We are excited to welcome Lance to our Board of Directors," said David King, Chairman of the Board, Privia Health Group, Inc. "Lance brings extensive technology strategy and digital transformation experience to the Board, including IT governance, infrastructure management and cybersecurity. We believe his expertise will be invaluable to Privia Health as

    7/8/25 9:00:00 AM ET
    $LH
    $PRVA
    Medical Specialities
    Health Care
    Medical/Nursing Services

    SOLVD Health Appoints Mike Aicher and Vince Cebula to Board of Directors to Support Next Phase of Growth

    SOLVD Health (SOLVD), a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, has appointed diagnostics pioneer Mike Aicher and strategic advisor Vince Cebula to its Board of Directors. Their combined leadership in molecular diagnostics, healthcare technology, and growth-stage investment will support the company's continued expansion as it scales access to personalized health insights and accelerates development of its precision diagnostics platform. Aicher's expertise in building and scaling diagnostic platforms will be instrumental as SOLVD Health expands its personalized health solutions. He brings more than three decades of executiv

    5/12/25 9:00:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp CFO Glenn Eisenberg Announces Plans to Retire

    Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to the CEO through April 2025 to ensure a seamless transition of his current role and assist with strategic initiatives underway within the company.

    11/19/24 7:00:00 AM ET
    $BGNE
    $LH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities